 |
市場調査レポート
商品コード
1463332
バイオマーカーの世界市場規模、シェア、成長分析、タイプ別、用途別、疾患別- 産業予測、2024年～2031年Global Biomarkers Market Size, Share, Growth Analysis, By Type(Safety, Efficacy), By Application(Diagnostics, Drug discovery & development), By Disease(Cancer, Cardiovascular Diseases) - Industry Forecast 2024-2031 |
||||||
| バイオマーカーの世界市場規模、シェア、成長分析、タイプ別、用途別、疾患別- 産業予測、2024年～2031年 |
|
出版日: 2024年04月08日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
バイオマーカーの世界市場規模は、2022年に669億7,000万米ドルと評価され、2023年の758億8,000万米ドルから2031年には2,060億4,000万米ドルに成長し、予測期間中（2024年～2031年）のCAGRは13.3%で成長する見通しです。
コンパニオン診断の重要性の高まり、がん罹患率の上昇、バイオマーカー研究のための資金調達の増加、継続的な調査の結果得られた重要な発見など、多くの要因によって成長が促進されると予想されます。例えば、2022年10月、ボストン大学の研究者らは、肺がんの新しいバイオマーカーを創出するために、米国立衛生研究所から460万米ドルの資金提供を受けた。技術的進歩によるバイオマーカーに基づく診断法の開拓も市場拡大を促進する要因の一つです。研究開発により、がん、心血管、免疫、神経疾患など幅広い疾患の治療に有効な薬剤の開発が可能になります。また、特定の病気を回避し、早期に発見する方法の理解にも役立ちます。この分野への投資は官民ともに増加していることが確認されています。例えば、2022年3月、Quanterix Corp.は、アルツハイマー病の診断用血漿検査の作成を促進するため、アルツハイマー病創薬財団から資金提供を受けたと発表しました。今後数年間で、感染症の診断におけるバイオマーカーの使用は大幅に増加すると予測されています。例えば、2021年のFrontiers in Microbiologyによれば、ライノウイルス、インフルエンザ感染、結核、HIV、マラリア、エボラ出血熱、ヘンドラウイルスなどの病気を検出するためのマイクロRNAベースのバイオマーカーの可能性が発見されています。これらのmiRNAベースのマーカーの目的は、感染症の早期発見に役立つことです。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- 二次データソースと一次データソース
- 市場規模の推定
- 市場の危機と限界
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主な投資の分析
- 主な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
バイオマーカーの世界市場：タイプ別
- 市場概要
- 安全性
- 効能
- 検証
バイオマーカーの世界市場：用途別
- 市場概要
- 診断
- 医薬品の発見・開発
- パーソナライズ医療
- その他
バイオマーカーの世界市場：疾患別
- 市場概要
- がん
- 心血管疾患
- 神経疾患
- 免疫疾患
バイオマーカーの世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
- ラテンアメリカ
- ブラジル
- その他のラテンアメリカ
- 中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他の中東・アフリカ
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- F. Hoffmann-La Roche AG
- Thermo Fisher Scientific Inc.
- Agilent Technologies, Inc.
- QIAGEN N.V.
- Bio-Rad Laboratories, Inc.
- Merck & Co., Inc.
- PerkinElmer, Inc.
- Illumina, Inc.
- BD（Becton, Dickinson and Company）
- Myriad Genetics, Inc.
- Siemens Healthineers AG
- Danaher Corporation
- Biomerieux SA
- Waters Corporation
- Abbott Laboratories
- Sysmex Corporation
- Bio-Techne Corporation
- Charles River Laboratories International, Inc.
- Eurofins Scientific SE
- Pacific Biomarkers, Inc.
Global Biomarkers Market size was valued at USD 66.97 billion in 2022 and is poised to grow from USD 75.88 billion in 2023 to USD 206.04 billion by 2031, growing at a CAGR of 13.3% during the forecast period (2024-2031).
The company's growth is expected to be fueled by a number of factors, such as the growing significance of companion diagnostics, the rising incidence of cancer, increased financing for biomarker research, and significant discoveries made as a result of continuing research. For example, in October 2022, researchers at Boston University received USD 4.6 million in funding from the National Institutes of Health to create new biomarkers for lung cancer. The development of biomarker-based diagnostics through technical advancement is another factor driving market expansion. Research enables the development of effective medications to treat a wide range of ailments, such as cancer, cardiovascular, immunological, and neurological conditions. It also helps in understanding how to avoid and detect a certain disease early on. It has been observed that both public and private investment in the sector has increased. For example, in March 2022, Quanterix Corp. announced that funding had been provided by the Alzheimer's Drug Discovery Foundation to expedite the creation of a diagnostic plasma test for Alzheimer's disease. The use of plasma-based biomarkers in clinical settings to diagnose Alzheimer's disease is quickly approaching.In the upcoming years, it is projected that the use of biomarkers in the diagnosis of infectious diseases would increase significantly. For example, potential MicroRNA-based biomarkers for the detection of diseases like rhinoviruses, influenza infections, tuberculosis, HIV, malaria, Ebola, and Hendra virus have been discovered, according to Frontiers in Microbiology in 2021. The goal of these miRNA-based markers is to help detect infectious diseases early on.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biomarkers Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Biomarkers Market Segmental Analysis
The global biomarkers market is segmented based on type, application, disease, and region. In terms of type, the market is classified into safety, efficacy, and validation. With respect to application, the market is categorized into diagnostics, drug discovery & development, personalized medicine, and others. In terms of disease, the market is segmented into cancer, cardiovascular diseases, neurological diseases, and immunological diseases. Regionwise, the global biomarkers market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.
Drivers of the Global Biomarkers Market
Because customized medicine enables more individualized and successful patient care, its demand is rising. Because they can be used to identify patient-specific biological signals that can inform treatment decisions, biomarkers are essential to personalized medicine.
Restraints in the Global Biomarkers Market
The process of finding and developing biomarkers is not standardized, which might cause variations in the accuracy and dependability of biomarker tests. This may make it more difficult for biomarkers to be used in clinical settings and may also cause problems with regulations.
Market Trends of the Global Biomarkers Market
Tests called companion diagnostics are intended to find biomarkers that suggest whether or not a patient may benefit from a specific treatment. The significance of these tests in personalized medicine and drug development is growing. Because of this, the companion diagnostics industry is expanding quickly, and numerous pharmaceutical companies are collaborating with diagnostic companies to create and promote these tests.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Biomarkers Market by Type
- Market Overview
- Safety
- Efficacy
- and Validation
Global Biomarkers Market by Application
- Market Overview
- Diagnostics
- Drug discovery & development
- Personalized Medicine
- and Others
Global Biomarkers Market by Disease
- Market Overview
- Cancer
- Cardiovascular Diseases
- Neurological Diseases
- and Immunological Diseases
Global Biomarkers Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- F. Hoffmann-La Roche AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Agilent Technologies, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- QIAGEN N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Rad Laboratories, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PerkinElmer, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Illumina, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BD (Becton, Dickinson and Company)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Myriad Genetics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Siemens Healthineers AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Danaher Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biomerieux SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Waters Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abbott Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sysmex Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Techne Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Charles River Laboratories International, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eurofins Scientific SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pacific Biomarkers, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
